Seres Therapeutics (MCRB) Stock
Developer of microbiome treatments for gut and overall health. Here's the price, business snapshot, and what's worth knowing about Seres Therapeutics in October 2026.
Seres Therapeutics (MCRB) is a small-cap biotechnology company developing microbiome-based therapeutics that aim to modulate the gut ecosystem to treat gastrointestinal and systemic conditions. Investors should know the firm is research- and pipeline-driven, with value tied to clinical trial progress, partnerships and regulatory milestones rather than steady revenues. As with many biotech companies of this size (market cap ≈ $164M), the share price can be highly volatile and subject to binary outcomes from clinical data and regulatory decisions. The business may pursue collaborations or licensing to fund development and scale commercialisation. For investors assessing Seres, focus on trial design, cash runway, partnership agreements and regulatory feedback. This information is educational only — not personal financial advice. Biotech investing carries significant risk: values can rise and fall and past performance is not a guide to future returns. Consider your risk tolerance and seek professional advice if needed before making investment decisions.
Seres Therapeutics (MCRB) Stock Forecast
Analyst price target, next 12 months
$7.65
+160.2% vs today's $2.94
Price range over the last 12 months
Close to its 12-month low
Analysts covering Seres Therapeutics have a consensus 12-month target of $7.65, above the current price of $2.94.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying SERES THERAPEUTICS stock due to its promising growth potential.
Financial Health
Seres Therapeutics has low revenue, but its cash flow per share is relatively strong.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Pipeline news and trial readouts can move the stock substantially, though outcomes are uncertain and may not lead to commercial success.
Microbiome Opportunity
Interest in microbiome therapeutics is growing as a new modality for GI and systemic conditions, but scientific and regulatory hurdles remain.
High Risk, High Uncertainty
Small market cap and limited revenues mean financing needs and binary outcomes are likely; consider suitability and seek professional advice where needed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
